Analysts: Stallergenes' approval may expand the market for allergy tablets

The fact that French company Stallergenes Greer can now also provide a tablet treatment for dust mite allergies in several European markets may ultimately benefit ALK, according to two analysts.
Photo: Stallergenes Greer/PR
Photo: Stallergenes Greer/PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

Carnegie Investment Bank Equity Analyst Jesper Ilsøe notes that the US Food and Drug Administration approval of Stallergenes Greer's tablet for dust mite allergies may lead to a further expansion of the market for treating allergies with tablets, which is currently relatively small.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading